Companies › VectivBio
1 active drug program in 2 registered trials: 2 Phase 3; Gastroenterology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Apraglutide GLP-2 receptor agonist | GLP2R | Phase 3 | Short Bowel Syndrome; Short Bowel Syndrome (SBS) | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05018286 | Apraglutide | Phase 3 | Short Bowel Syndrome | Gastroenterology | Oct 2027 |
| NCT07742735 | Apraglutide | Phase 3 | Short Bowel Syndrome (SBS) | Gastroenterology | Oct 2028 |
Camurus Altimmune Pharmicell Akero Therapeutics LyGenesis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.